Compare Fortuna Mining Corp. Common Shares (FSM) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortuna Mining Corp. Common Shares vs Organon & Co. Common Stock — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.16 (market cap $3.12B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Fortuna Mining Corp. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| FSM | OGN | |
|---|---|---|
Market Cap | $3.12B | $3.62B |
Volume | 2,648,950 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $13.81 |
52-Week Low | $7.84 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $2.74B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortuna Mining (FSM) trades at $10.58, down 1.67% on the day, amid a bearish technical signal. The company reported strong 2025 results with $947M revenue and $287M net income, but recent quarters have missed EPS expectations. Analyst consensus is bullish with 4 buy ratings, while technical indicators show mixed signals with a bearish moving average trend but neutral oscillators.
FSM presents a value opportunity with low P/E of 8.89 and robust profitability margins, but faces risks from production volatility and execution of growth projects. The stock's near-term performance hinges on Q3 2026 earnings and progress toward its 500,000-ounce gold production target by 2028.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fortuna Mining Corp. Common Shares
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
